In this study, we found that Tim-3 inhibits MHC-II expression and antigen presentation with EAE model amelioration, which indicates that the Tim-3-targeting therapeutic strategy could have more potential for cancers and infectious and autoimmune diseases. This evidence concerns the gene HAVCR2 and cancer.